Considerations Regarding the Present and Future Roles of Colonoscopy in Colorectal Cancer Prevention Douglas K. Rex, Emely Eid Clinical Gastroenterology and Hepatology Volume 6, Issue 5, Pages 506-514 (May 2008) DOI: 10.1016/j.cgh.2008.02.025 Copyright © 2008 AGA Institute Terms and Conditions
Figure 1 All forms of non-colonoscopic screening rely on the efficacy of colonoscopy to detect adenomas and cancer. FOBT, fecal occult blood test; DNA, deoxyribonucleic acid; DCBE, double contrast barium enema; CTC, Computed tomographic colonography. Clinical Gastroenterology and Hepatology 2008 6, 506-514DOI: (10.1016/j.cgh.2008.02.025) Copyright © 2008 AGA Institute Terms and Conditions
Figure 2 Incident cases of colorectal cancer per 1000 years of patient observation. NPS, National Polyp Study21; PPT, Polyp Prevention Trial32; WB, Wheat-Bran Fiber Trial31; Funen, Funen adenoma follow-up study33; Chemo, combined results of 3 U.S. chemoprevention trials.34 Clinical Gastroenterology and Hepatology 2008 6, 506-514DOI: (10.1016/j.cgh.2008.02.025) Copyright © 2008 AGA Institute Terms and Conditions
Figure 3 Impact of diagnosis-only imaging tests (such as CT colonography or capsule colonoscopy) on colorectal cancer prevention may depend on their impact on screening adherence rates. Improved adherence should reduce colorectal cancer incidence. Displacement of patients from colonoscopy without improved adherence could increase cancer incidence rates. Clinical Gastroenterology and Hepatology 2008 6, 506-514DOI: (10.1016/j.cgh.2008.02.025) Copyright © 2008 AGA Institute Terms and Conditions